
David Meeker, Rhythm Pharmaceuticals CEO
Rhythm says oral rare obesity drug clears Phase 2 test, plans tweaks to formulation
Rhythm Pharmaceuticals said Wednesday its oral candidate for a rare form of obesity produced “statistically significant and clinically meaningful” reductions in BMI in a mid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.